Medical Crossfire: Global Perspectives on Recent Data in Hormone Receptor - Positive Breast Cancer: Individualizing and Optimizing Use of CDK Inhibitors

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical .. Read more education for physicians. Physicians' Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. In this activity, 4 key thought leaders explore the role of CDK4/6 inhibitors in the management of patients with hormone receptor–positive (HR+) breast cancer. The discussion will cover evolving evidence in the metastatic setting and strategies for individualizing and optimizing treatment, as well as emerging data in the setting of early-stage breast cancer and how recent results will impact the management of patients with high-risk disease. This lively discussion will help place new developments into clinical context to help optimize care for patients with HR+ breast cancer. This educational activity is directed toward medical oncologists who treat patients with breast cancer. Other physicians, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of breast cancer are also invited to participate.